721.221 Feeder Cells for NK and CAR-Modified Cell Expansion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing CAR-modified T cell therapies face challenges due to poor cytotoxicity of autologous T cells isolated from immune-compromised cancer patients and the risk of graft-versus-host disease, limiting their effectiveness and applicability.
Innovation Solution
Modified 721.221 cells expressing cytokines like mIL-21 and IL-15Rα are used to enhance the cytotoxicity and expandability of NK and T cells, which are then administered to patients to treat various cancers and infectious diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR-modified T cell therapy is used to treat cancer, then therapeutic efficacy is improved, but the risk of graft-versus-host disease increases and cytotoxicity of autologous T cells is poor
Solution Approach 1:
The patent uses modified 721.221 feeder cells as an intermediary to culture and expand NK cells ex vivo. These feeder cells are engineered to express membrane-bound IL-21 and soluble IL-15, creating an optimized culture environment that enhances NK cell expansion and cytotoxicity without requiring autologous T cells from immunocompromised patients, thereby avoiding graft-versus-host disease risk while maintaining therapeutic efficacy
Solution Approach 2:
The patent modifies the culture conditions by changing the expression parameters of cytokines on feeder cells - specifically expressing membrane-bound IL-21 (mIL-21) and soluble IL-15 on 721.221 cells. This parameter change in the culture system leads to improved NK cell expansion and cytotoxic function, resolving the contradiction between therapeutic efficacy and safety
2Adaptability or versatility
If autologous T cells are isolated from immune-compromised cancer patients, then patient-specific treatment is achieved, but cytotoxicity is poor and effectiveness is limited
Solution Approach 1:
The patent introduces modified 721.221 feeder cells as an intermediary culture system that expresses membrane-bound IL-21 and soluble IL-15. This intermediary system enables effective ex vivo expansion and activation of patient-specific NK cells without requiring isolation of poor-quality autologous T cells from immunocompromised patients, thereby maintaining patient-specific adaptability while improving cytotoxicity
Solution Approach 2:
The patent uses allogeneic 721.221 feeder cells as a surrogate system to provide the necessary cytokine environment for NK cell expansion, copying the function of optimal culture conditions without relying on the compromised autologous T cell population from patients, thus achieving both patient-specific treatment and high cytotoxicity
Data Source
AI summary
Disclosed herein are methods and compositions for generating immunotherapeutic cells (e.g., NK and T cells) with enhanced cytotoxicity and capacity for expansion thereof. The methods and compositions disclosed herein can further be used for enhanced expansion of CAR-modified NK and T cells with increased cytotoxicity.